

25th January, 2018

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
---	---

Re: Outcome of the Board Meeting

Dear Madam/Sir,

At the Board meeting held today, the Board has inter alia approved and taken on record Unaudited Financial results for the third quarter ended 31st December 2017. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

- i. Press Release being issued on the Results for the third quarter ended 31st December 2017;
- ii. Unaudited Consolidated Financial Results for the third quarter ended 31st December 2017;
- iii. Limited Review Report from Auditors M/s BSR & Co. LLP on the unaudited Consolidated Financial Results for the third quarter ended 31st December 2017;
- iv. Unaudited Standalone Financial Results for the third quarter ended 31st December 2017;
- v. Limited Review Report from Auditors M/s BSR & Co. LLP on the unaudited Standalone Financial Results for the third quarter ended 31st December 2017.

Kindly note that the meeting of the Board of Directors commenced at 12.30 p.m. and concluded at 2.30 p.m.

Kindly take the above on your records.

Thanking You,
Yours faithfully,

GAURANG SHAH
AVP - Legal &
Company Secretary

Encl.: a/a

Press Release**Q3 Income from Operations at Rs. 587 cr., PAT at Rs. 147 cr.**
(3rd Quarter & 9 months, FY 2018 Consolidated Results)

Mumbai, 25th January, 2018: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 3rd quarter & 9 months ended 31st December 2017.

Q3 FY 2018 performance highlights (consolidated - compared to Q3 FY 2017)

- Income from operations at Rs. 587 cr. against Rs. 533 cr., up 10%.
- EBITDA at Rs. 204 cr. against Rs. 177 cr., up 15%, EBITDA at 35% of revenue.
- Profit after tax at Rs. 147 cr., against Rs. 142 cr., up 4%, PAT at 25% of revenue.
- Total comprehensive income at Rs. 147 cr. against Rs. 142 cr. up 4%.

9 Months, FY 2018 performance highlights (consolidated - compared to 9 Months, FY 2017)

- Income from operations at Rs. 1,601 cr. against Rs. 1,525 cr., up 5%.
- EBITDA at Rs. 519 cr. against Rs. 526 cr., down 1%, EBITDA at 32% of revenue.
- Profit after tax at Rs. 374 cr., against Rs. 393 cr., down 5%, PAT at 23% of revenue.
- Total comprehensive income at Rs. 377 cr. against Rs. 391 cr. down 4%.

Commenting on the results, Mr. Yogesh Agrawal, Managing Director said:

“We are pleased with our branded generic business performance in emerging markets which has posted healthy growth, in line with our expectation. We continue to maintain our aggression on the branded generic business by launching new products, increasing the productivity and increasing the coverage.

Despite the challenging price erosion environment in US market, we have performed well during the quarter.

We continue to build world class facilities to meet our growth requirements. Second phase of our Guwahati facility is nearing completion.”

India

For Q3 FY 2018, India's branded generic sales (excluding institution) was Rs. 155 cr. posting growth of 4% and total India sales (including institution), was Rs. 160 cr., growth of 4%.

For 9 months FY 2018, India branded sales (excluding institution) was Rs. 462 cr. same as last year and total India sales (including institution) was Rs. 481 cr., growth of 1%.

As per IMS MAT December 2017, we have posted healthy growth of 13% in Cardiology (segment growth of 6%), 17% in Ophthalmology (segment growth of 9%), (-1%) in Dermatology (segment growth of 16%) and 9% in Pain Management (segment growth of 3%).

Exports

During Q3 FY 2018, export sales were Rs. 415 cr. (growth of 15%). Africa contributed Rs. 180 cr. (de-growth of 14%), Asia contributed Rs. 161 cr. (growth of 79%) and US contributed Rs. 71 cr. (growth of 21%).

For 9 Months FY 2018, exports sales were Rs. 1,086 cr. (growth of 8%). Africa contributed Rs. 567 cr. (de-growth of 2%), Asia contributed Rs. 361 cr. (growth of 29%) and US contributed Rs. 152 cr. (growth of 9%).

In US, we received 1 ANDA final approval, commercialized 2 products and filed 1 ANDA with US FDA during Q3 FY 2018. With this, company has 17 products commercialized out of 20 final ANDA approvals, has 2 tentative approvals and 16 ANDAs awaiting approval with US FDA at the end of Q3 FY 2018. Company plans to file 10-12 ANDAs during this financial year.

R&D

During Q3 FY 2018, R&D expenses were Rs. 43 cr., 7% of operating revenue (Q3 FY 2017 Rs. 45 cr.). For 9 Months FY 2018, R&D expenses were Rs. 138 cr., 9% of operating revenue (9 months FY 2017 Rs. 114 cr.).

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 850+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius.

For last 5 years, company has posted healthy performance with its consolidated total income growing at 21% CAGR and net profit at 46% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter— www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2017

₹ in Crore

Particulars	3 months ended			9 months ended		Year Ended
	31/12/2017	30/09/2017	31/12/2016	31/12/2017	31/12/2016	31/03/2017
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	587.05	540.38	533.11	1,600.55	1,524.83	2,001.64
Other income	15.15	9.18	19.19	20.09	21.47	23.86
Total Income	602.20	549.56	552.30	1,620.64	1,546.30	2,025.50
Expenses						
Cost of materials consumed	87.57	82.33	97.72	264.35	297.66	377.85
Purchases of stock-in-trade	22.08	19.01	19.41	57.02	40.22	47.36
Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.34	7.69	(10.71)	(8.72)	(15.55)	(10.62)
Employee benefits expense	95.22	89.42	77.44	271.32	219.92	295.42
Finance costs	0.14	0.09	0.28	0.30	0.97	1.36
Depreciation and amortisation expense	14.98	14.55	15.30	42.95	42.29	61.21
Other expenses	184.34	158.20	171.81	498.89	456.60	604.75
Total Expenses	404.67	371.29	371.25	1,126.11	1,042.11	1,377.33
Profit before tax	197.53	178.27	181.05	494.53	504.19	648.17
Tax Expense						
Current Tax	46.77	36.41	40.94	107.01	126.82	157.49
Deferred Tax	3.29	9.97	(2.49)	13.37	(15.44)	(16.15)
Profit for the period	147.47	131.89	142.60	374.15	392.81	506.83
Other Comprehensive Income (OCI)						
Items that will not be reclassified to profit or loss (net)	(0.03)	(0.03)	(0.06)	(0.09)	(0.17)	(0.11)
Items that will be reclassified to profit or loss	(0.75)	1.71	(0.87)	2.80	(1.39)	(2.42)
Other Comprehensive Income for the year, net of tax	(0.78)	1.68	(0.93)	2.71	(1.56)	(2.53)
Total Comprehensive Income for the period	146.69	133.57	141.67	376.86	391.25	504.30
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.69	17.69	17.69	17.69	17.69	17.69
Other Equity	NA	NA	NA	NA	NA	1,549.99
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	16.76	14.99	16.19	42.51	44.64	57.59
(b) Diluted - in ₹	16.75	14.98	16.20	42.50	44.63	57.58

Notes :

- Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 25 January 2018.
- Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended 31 December 2017.
- The consolidated audited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- The Company has changed the method of depreciating Property, plant & equipment from Written Down Value (WDV) to Straight Line Method (SLM) w.e.f. 1 April 2017 to reflect the usage pattern of these assets. This has resulted in depreciation during the quarter being lower by ₹ 10.46 crores (nine month ₹ 31.31 cr).
- Deferred tax includes MAT credit of ₹ 11 Crores.
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- There are no exceptional items.
- The amalgamation of Gabs Investments Private Limited ('Gabs') with the Company as approved by Board of Directors on 18 March 2017, has also been approved by the Shareholders of both the Companies in their meeting held on 10 October 2017. Gabs holds 83,92,262 equity shares in the Company, representing about 9.54% of the total paid up capital, against which Company will issue same number of shares to the shareholders of Gabs. Amalgamation is subject to approval of regulatory authorities as prescribed in law. Hence, no effect of the same is given in the financial statements.
- The Standalone Financial Results are available on the company's website www.ajantapharma.com.
- Previous period's figures have been regrouped wherever necessary.

By order of the Board
For Ajanta Pharma Ltd.



Yogesh M. Agrawal
Managing Director

Mumbai, 25 January 2018

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Ajanta Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors Ajanta Pharma Limited

We have reviewed the accompanying Statement of unaudited consolidated financial results for the quarter and nine months ended 31 December 2017 ('the Statement') of Ajanta Pharma Limited ('the Company') and its subsidiaries as listed in Annexure – 1 (the Company and its subsidiaries constitute 'the Group'), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 25 January 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the financial results and other financial information of the subsidiaries, whose financial results and other financial information reflect total revenue of Rs. 178.98 crores and Rs 462.68 crores for the quarter and ninth months ended 31 December 2017. Total profit after tax of the group of Rs. 31.29 and 69.16 crores for the quarter and ninth months ended 31 December 2017 as considered in the Statement. These financial results and other financial information have not been subjected to limited review by their auditors and have been presented based on financial information compiled by the Company's management. Our review opinion on the consolidated financial results, in so far as it relates to these entities, is solely based on such financial information compiled by the management. Our conclusion is not modified in respect of this matter.

The unaudited consolidated financial results for the corresponding quarter and nine months ended 31 December 2016 and the audited consolidated financial results for the year ended 31 March 2017 included in the Statement, were reviewed/ audited by the predecessor auditor, whose limited review report dated 24 January 2017 and audit report dated 3 May 2017 expressed an unmodified opinion on those unaudited/ audited consolidated financial results, respectively.



**Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Ajanta Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
(Continued)**

Ajanta Pharma Limited

Based on our review conducted as above and based on the consideration of the reports of the other auditors as highlighted above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sreeja Marar

Partner

Membership No: 111410

Mumbai
25 January 2018

**Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Ajanta Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
(Continued)**

Ajanta Pharma Limited

Annexure – 1

The Statement includes the results of the following entities

Names of the Entities

Ajanta Pharma (Mauritius) Ltd.

Ajanta Pharma USA Inc.

Ajanta Pharma Philippines Inc.

Ajanta Pharma UK Ltd.

Ajanta Pharma Nigeria Ltd.

Ajanta Pharma (Mauritius) Intl. Ltd.



Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December 2017

₹ in Crore

Particulars	3 months ended			9 months ended		Year Ended
	31/12/2017	30/09/2017	31/12/2016	31/12/2017	31/12/2016	31/03/2017
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	500.78	469.14	508.60	1,367.85	1,404.21	1,822.71
Other income	64.69	7.93	51.08	69.26	59.59	66.95
Total Income	565.47	477.07	559.68	1,437.11	1,463.80	1,889.66
Expenses						
Cost of materials consumed	87.27	81.14	96.93	262.21	294.17	373.31
Purchases of stock-in-trade	26.34	14.64	18.10	59.57	43.68	59.23
Changes in inventories of finished goods, work-in-progress and stock-in-trade	4.95	10.84	12.79	(16.60)	13.28	7.29
Employee benefits expense	84.20	82.15	69.28	246.13	200.69	269.78
Finance costs	0.10	0.05	0.25	0.19	0.87	1.24
Depreciation and amortisation expense	14.34	13.95	14.73	41.22	40.61	59.48
Other expenses	144.44	122.93	136.34	387.39	359.49	478.68
Total Expenses	361.64	325.70	348.42	980.11	952.79	1,249.01
Profit before tax	203.83	151.37	211.26	457.00	511.01	640.65
Tax Expense						
Current Tax	39.92	32.35	39.00	94.00	117.53	136.98
Deferred Tax	(0.68)	11.32	1.28	13.98	1.64	3.86
Profit for the period	164.59	107.70	170.98	349.02	391.84	499.81
Other Comprehensive Income (OCI)						
Items that will not be reclassified to profit or loss	(0.04)	(0.05)	(0.09)	(0.13)	(0.26)	(0.17)
Items that will be reclassified to profit or loss	0.01	0.02	0.03	0.04	0.09	0.06
Other Comprehensive Income for the year, net of tax	(0.03)	(0.03)	(0.06)	(0.09)	(0.17)	(0.11)
Total Comprehensive Income for the period	164.56	107.67	170.92	348.93	391.67	499.70
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.69	17.69	17.69	17.69	17.69	17.69
Other Equity	NA	NA	NA	NA	NA	1,486.25
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	18.70	12.24	19.42	39.66	44.53	56.79
(b) Diluted - in ₹	18.70	12.23	19.42	39.65	44.52	56.78

Notes :

- Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 25 January 2018.
- Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended 31 December 2017.
- Other income includes :

	3 months ended			9 months ended		Year Ended
	31/12/2017	30/09/2017	31/12/2016	31/12/2017	31/12/2016	31/03/2017
Dividend from subsidiaries (₹ in Crore)	49.65	-	33.38	49.65	33.38	43.18

- The Company has changed the method of depreciating Property, plant & equipment from Written Down Value (WDV) to Straight Line Method (SLM) w.e.f. 1 April 2017 to reflect the usage pattern of these assets. This has resulted in depreciation during the quarter being lower by ₹ 10.46 crores (nine month ₹ 31.31 cr.)
- Deferred tax includes MAT credit of ₹ 11 Crores.
- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- There are no exceptional items.
- The amalgamation of Gabs Investments Private Limited ('Gabs') with the Company as approved by Board of Directors on 18 March 2017, has also been approved by the Shareholders of both the Companies in their meeting held on 10 October 2017. Gabs holds 83,92,262 equity shares in the Company, representing about 9.54% of the total paid up capital, against which Company will issue same number of shares to the shareholders of Gabs. Amalgamation is subject to approval of regulatory authorities as prescribed in law. Hence, no effect of the same is given in the financial statements.
- Previous period's figures have been regrouped wherever necessary.

By order of the Board
For Ajanta Pharma Ltd.



Yogesh M. Agrawal
Managing Director


Mumbai, 25 January 2018

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Ajanta Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors Ajanta Pharma Limited

We have reviewed the accompanying Statement of unaudited standalone financial results for the quarter and nine months ended 31 December 2017 ('the Statement') of Ajanta Pharma Limited ('the Company'), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 25 January 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The unaudited standalone financials results for the corresponding Quarter and Nine month ended 31 December 2016 and the audited standalone financial results for the year ended 31 March 2017 included in the Statement, were reviewed/ audited by the predecessor auditor, whose limited review report dated 24 January 2017 and audit report dated 3 May 2017 expressed an unmodified opinion on those unaudited/ audited standalone financial results, respectively.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sreeja Marar
Partner

Membership No: 111410

Mumbai
25 January 2018